Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

Clinical trial NCT01281098 · COMPLETED

Trial details

NCT number: NCT01281098
Sponsor: Association for Innovation and Biomedical Research on Light and Image
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

High Risk Proliferative Diabetic Retinopathy Diabetes Mellitus Type I Diabetes Mellitus Type II

Start date: 2010-03-01
Primary completion: 2012-10-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.